Lymph Node Targeted Nanoparticles

Technology #18243

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Reduced systemic toxicity via nanoparticle drug delivery system.
Categories
Inventors
Professor Darrell Irvine
Department of Biological Engineering, MIT
External Link (irvine-lab.mit.edu)
Professor Francesco Stellacci
Department of Materials Science and Engineering, MIT
Yu-Sang Yang
Koch Institute for Integrative Cancer Research, MIT
Ahmet Bekdemir
École Polytechnique Fédérale de Lausanne
Managed By
Jon Gilbert
MIT Technology Licensing Officer
Patent Protection

Lymph Node Targeted Nanoparticles

PCT Patent Application WO 2017-070676

Applications

This invention delivers small molecules to lymph nodes for improved immunotherapeutic treatments. It can also be used for better vaccine outcomes, lymphatic imaging, or to target cell types within the lymphatic system via antibody conjugation.

Problem Addressed

Amplification of a patient's immune system is a well-established treatment strategy to combat disease. A bolstered immune system is most effectively achieved by targeting lymph nodes as they are heavily populated with leukocytes. Furthermore, slight imperfections in immunotherapeutics can induce fatal conditions including: extreme local inflammation, systemic inflammation, or septic-shock. Targeted delivery to lymph nodes allows molecules to be used more efficiently and to be administered in lower doses, which can reduce the potential for adverse reactions. This invention is amphiphilic nanoparticles (amph-NPs) which can deliver drugs directly to lymph nodes to significantly enhance vaccine and immunotherapy outcomes.

Technology

Hydrophobic drugs in organic solvent are mixed with an aqueous suspension of amph-NPs and dialyzed to remove the organic solvent leading to partitioning of the drug into the hydrophobic pockets of the amph-NP ligand shell. This approach allows loading of a wide variety of drugs nearly insoluble in aqueous solutions - a highly desirable feature as many molecules currently being investigated as new pharmaceuticals, though potent, well-defined, and cost effective, are hydrophobic, and, therefore, rapidly cleared in vivo, thus requiring high and often toxic doses to achieve a desired effect. This technology dramatically reduces off-target delivery and toxicity and allows cargo to be utilized more effectively and at a lower dose, thereby potentially increasing the maximum allowable clinical dose for improved therapeutic efficiency. Furthermore, these NPs are less than 5nm, which allows for efficient clearance renally preventing long-term tissue accumulation. The Inventors performed a single subcutaneous injection near the base of the tail in mice and found 10% of the total injection dose in the draining lymph node - a 12-fold increase in NP lymph node accumulation compared to control PEG-NPs.

Advantages

  • Lymph node delivery allows lower doses decreasing potential off-target toxicity
  • Hydrophobic cargo capability
  • Excellent stability in post-synthesis storage
  • Safe, potent, and versatile vector